Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Tuesday. The firm issued a hold rating on the stock.

Can-Fite BioPharma Price Performance

Shares of NYSE:CANF opened at $2.07 on Tuesday. The stock has a market cap of $7.33 million, a P/E ratio of -1.16 and a beta of 1.53. Can-Fite BioPharma has a 1-year low of $1.71 and a 1-year high of $3.33. The firm has a fifty day moving average price of $2.15 and a 200 day moving average price of $2.10.

Can-Fite BioPharma (NYSE:CANF) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.20 million. Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. Sell-side analysts expect that Can-Fite BioPharma will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Armistice Capital LLC purchased a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned about 4.36% of Can-Fite BioPharma at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.